ClinicalTrials.gg
CompletedNCT01327911Updated Nov 22, 2016

Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

A Phase 1 interventional study of NT-501 implant in Idiopathic Juxtafoveal Telangiectasia, sponsored by Neurotech Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2016-11-22.

Sponsored by Neurotech Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.

Read the detailed description

Protocol for Extended Follow-up of a Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasia Type 2 (MacTel)

02

Conditions studied

  • Idiopathic Juxtafoveal Telangiectasia

Keywords

  • Mactel
  • Macular Telangiectasia Type 2
03

In context

Lead sponsor

Neurotech Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant must be offered sufficient opportunity to review the form, agree to the form's contents and sign the protocol's informed consent;
  • The participant must have bilateral MacTel;
  • Women of and all men must agree to use an effective form of during the study;
  • Participant must be medically able to undergo ophthalmic surgery for ECT implant;
  • The participant's best-corrected visual acuity 64 letters or better (20/50 or better) in the study eye;

Exclusion criteria

Exclusion Criteria:

  • Participant is \< 21 years of age;
  • Participant is medically unable to comply with study procedures or follow- up visits;
  • Participant has evidence of ocular disease other than MacTel that may confound the outcome of the study (e.g., diabetic retinopathy with manifest macular edema, uveitis, etc.);
  • Participant has a chronic requirement (e.g., ≥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease, that in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted);
  • Participant has evidence of subretinal neovascularization in either eye;
  • Participant has evidence of central serous chorio-retinopathy (CSR) in either eye;
  • Participant has evidence of pathologic myopia in either eye;
  • Participant has had a vitrectomy, penetrating keratoplasty, trabeculectomy or trabeculoplasty;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Ciliary Neurotrophic Factor (CNTF)/NT-501

    Biological/Vaccine:NT-501 implant

    Biological: NT-501 implant

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Acuity

    Visual acuity decrease of \>=15 letters

    Time frame: 3,12, 24 and 36 months

Secondary outcomes

  1. Microperimetry

    Change of a 10dB at least one point either adjacent to a pre-existing scotoma or in a new area within the central 10 degrees on microperimetric testing

    Time frame: 12, 24 and 36 months

  2. OCT

    Change in en face area as measured by OCT

    Time frame: 12, 24, and 36 months

07

Study locations

2 sites
  • Jules Stein Eye Institute
    Los Angeles, California 90095, United States
  • Retina Associates of Cleveland
    Cleveland, Ohio 44122, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2011
First posted
Apr 4, 2011
Start
May 2011
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Last update
Nov 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01327911
Lead sponsor
Neurotech Pharmaceuticals
Collaborators
The Lowy Medical Research Institute Limited
Responsible party
Sponsor
First posted
Apr 4, 2011
Start date
May 2011
Primary completion
Sep 2016
Completion
Sep 2016
Last update
Nov 22, 2016

Study contacts

Weng Tao
study chair · Neurotech USA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciliary Neurotrophic Factor

Start the discussion